[HTML][HTML] Phosphatidylinositol 3-kinase p110δ expression in Merkel cell carcinoma
E Chteinberg, D Rennspiess, R Sambo… - Oncotarget, 2018 - ncbi.nlm.nih.gov
E Chteinberg, D Rennspiess, R Sambo, S Tauchmann, NWJ Kelleners-Smeets…
Oncotarget, 2018•ncbi.nlm.nih.govThe prognosis of stage III/IV Merkel cell carcinoma (MCC) is very poor. The
Phosphatidylinositol 3-kinase p110δ specific inhibitor idelalisib has recently been reported
to induce complete clinical remission in a stage IV MCC patient. Here we assessed the
expression of p110δ in primary MCC and MCC cell lines including its functionality.
Phosphatidylinositol 3-kinase p110δ specific inhibitor idelalisib has recently been reported
to induce complete clinical remission in a stage IV MCC patient. Here we assessed the
expression of p110δ in primary MCC and MCC cell lines including its functionality.
Abstract
The prognosis of stage III/IV Merkel cell carcinoma (MCC) is very poor. The Phosphatidylinositol 3-kinase p110δ specific inhibitor idelalisib has recently been reported to induce complete clinical remission in a stage IV MCC patient. Here we assessed the expression of p110δ in primary MCC and MCC cell lines including its functionality.
ncbi.nlm.nih.gov
以上显示的是最相近的搜索结果。 查看全部搜索结果